Skip to main content
. Author manuscript; available in PMC: 2013 Aug 5.
Published in final edited form as: Anticancer Res. 2010 Sep;30(9):3345–3353.

Figure 1.

Figure 1

(A). Effect of an NK-1R antagonist on weight change in an animal model of colitis-associated dysplasia (*P < 0.05; **P < 0.01; ***P < 0.001 versus vehicle-treated animals). Results are means ± SE; n = 22 per group. (B). Effect of an NK-1R antagonist on macroscopic damage score in an animal model of colitis-associated dysplasia. The average macroscopic score (including the presence of adhesions, thickness of the tissue, presence or absence of diarrhea, and grade of ulceration) was significantly decreased by administration of the antagonist (**P < 0.01). Results are means ± SE; n = 22 per group.